Cristina Ivanescu

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen et al. · Journal of Clinical Oncology · 2013 · 438 citations · Full text

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

David Cella, Viktor Grünwald, Bernard Escudier et al. · The Lancet Oncology · 2019 · 251 citations · Full text

Checkmate 214, Patient-reported Outcomes, Oncology +8

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

Yohann Loriot, Kurt Miller, Cora N. Sternberg et al. · The Lancet Oncology · 2015 · 191 citations

Urology, Health-related Quality, Pain Medicine +12

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

Bertrand Tombal, Fred Saad, David F. Penson et al. · The Lancet Oncology · 2019 · 105 citations · Full text

Urology, Patient-reported Outcomes, Medicine +8

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

David Cella, Robert J. Motzer, Cristina Suárez et al. · The Lancet Oncology · 2022 · 83 citations · Full text

Urology, Patient-reported Outcomes, Genitourinary Cancer +9